NO20101696L - Fremgangsmate for behandling av tumorer og metastaser ved bruk av en kombinasjon av anti-angiogenese og immunoterapi - Google Patents

Fremgangsmate for behandling av tumorer og metastaser ved bruk av en kombinasjon av anti-angiogenese og immunoterapi

Info

Publication number
NO20101696L
NO20101696L NO20101696A NO20101696A NO20101696L NO 20101696 L NO20101696 L NO 20101696L NO 20101696 A NO20101696 A NO 20101696A NO 20101696 A NO20101696 A NO 20101696A NO 20101696 L NO20101696 L NO 20101696L
Authority
NO
Norway
Prior art keywords
metastases
treatment
cytokine
tumors
immunotherapy
Prior art date
Application number
NO20101696A
Other languages
English (en)
Inventor
Stephen D Gillies
David A Cheresh
Holger N Lode
Ralph A Reisfeld
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20101696L publication Critical patent/NO20101696L/no
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Oppfinnelsen viser fremgangsmåter for behandling av tumorer og metastaser i pattedyr som trenger behandling og omfatter administrering av en terapeutisk mengde av en antagonist som er tilstrekkelig til å inhibere angiogenese sammen med en terapeutisk mengde av et anti-tumor immunoterapeutisk middel, slik som et anti-tumor antigen antistoff/cytokin fusjonsprotein, som har et cytokin og en rekombinant immunoglobulin polypeptidkjede som er tilstrekkelig til å utløse en cytokin spesifikk biologisk respons.
NO20101696A 1999-02-12 2010-12-03 Fremgangsmate for behandling av tumorer og metastaser ved bruk av en kombinasjon av anti-angiogenese og immunoterapi NO20101696L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11972199P 1999-02-12 1999-02-12
PCT/US2000/003483 WO2000047228A1 (en) 1999-02-12 2000-02-11 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies

Publications (1)

Publication Number Publication Date
NO20101696L true NO20101696L (no) 2001-10-09

Family

ID=22385967

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20013906A NO331072B1 (no) 1999-02-12 2001-08-10 Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
NO20101696A NO20101696L (no) 1999-02-12 2010-12-03 Fremgangsmate for behandling av tumorer og metastaser ved bruk av en kombinasjon av anti-angiogenese og immunoterapi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20013906A NO331072B1 (no) 1999-02-12 2001-08-10 Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.

Country Status (22)

Country Link
US (3) US7115261B1 (no)
EP (1) EP1156823B1 (no)
JP (2) JP4841727B2 (no)
KR (1) KR100704140B1 (no)
CN (1) CN1192796C (no)
AT (1) ATE412433T1 (no)
AU (1) AU776790B2 (no)
BR (1) BR0008161A (no)
CA (1) CA2360106C (no)
CZ (1) CZ303155B6 (no)
DE (1) DE60040651D1 (no)
DK (1) DK1156823T3 (no)
ES (1) ES2313883T3 (no)
HU (1) HU229520B1 (no)
MX (1) MXPA01008110A (no)
NO (2) NO331072B1 (no)
PL (1) PL200919B1 (no)
PT (1) PT1156823E (no)
RU (1) RU2236251C2 (no)
SI (1) SI1156823T1 (no)
SK (1) SK287357B6 (no)
WO (1) WO2000047228A1 (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
MXPA03007878A (es) * 2001-03-02 2004-07-08 Medimmune Inc Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina.
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030077247A1 (en) * 2001-09-20 2003-04-24 Schering Corporation Chemokines as adjuvants of immune response
ES2381025T3 (es) * 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
JP4502641B2 (ja) * 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
GB0217017D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 2
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20060234925A1 (en) * 2002-09-04 2006-10-19 Kazuhiko Imakawa Embryo implantation inhibitor
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7196061B2 (en) 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
ATE486610T1 (de) * 2004-07-09 2010-11-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
AU2005326226B2 (en) 2005-01-31 2010-11-11 Eci, Inc. Immunopotentiating agent
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
DK2913343T3 (en) * 2005-12-20 2018-11-26 Sbi Biotech Co Ltd Anti-ILT7 antibody
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
AU2008346734A1 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US20090220521A1 (en) * 2008-01-04 2009-09-03 Randolf Kerschbaumer Anti MIF Antibodies
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
CN102216323B (zh) * 2008-11-17 2016-08-03 哥本哈根大学 用于调节慢性炎症反应和治疗自身免疫性疾病的源自il-4的肽
ES2703714T3 (es) 2009-03-12 2019-03-12 Cancer Prevention & Cure Ltd Métodos de identificación, evaluación, prevención y terapia de enfermedades pulmonares y kits de los mismos, incluida la identificación, evaluación, prevención y terapia de enfermedades en base al género
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
PL2451279T3 (pl) * 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
CA2824252A1 (en) * 2011-02-10 2012-08-16 Roche Glycart Ag Improved immunotherapy
PE20140303A1 (es) 2011-02-10 2014-03-22 Roche Glycart Ag Polipeptidos interleuquina-2 mutantes
EP2702411A4 (en) * 2011-04-29 2015-07-22 Cancer Prevention & Cure Ltd METHODS OF IDENTIFYING AND DIAGNOSING PULMONARY DISEASES USING CLASSIFICATION SYSTEMS AND THEIR KITS
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
RU2013156435A (ru) 2011-07-06 2015-08-20 МорфоСис АГ Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения
US9309306B2 (en) 2011-08-23 2016-04-12 Roche Glycart Ag Anti-MCSP antibodies
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
CN102634485A (zh) * 2012-03-15 2012-08-15 上海市浦东新区公利医院 一种表达il-17的胶质瘤细胞株
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP2934555B1 (en) 2012-12-21 2021-09-22 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
CA2909576C (en) 2013-04-19 2023-07-18 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
JP6586087B2 (ja) * 2013-08-20 2019-10-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
SG11201609014TA (en) 2014-05-08 2016-12-29 Chugai Pharmaceutical Co Ltd Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US20170260285A1 (en) * 2014-11-24 2017-09-14 University Of Iowa Research Foundation Methods for treating cancer
WO2017002934A1 (ja) 2015-07-01 2017-01-05 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN106906184B (zh) * 2017-02-27 2021-04-23 广东昭泰体内生物医药科技有限公司 一种促进肺癌细胞生长的方法
EA201992326A1 (ru) * 2017-03-31 2020-03-13 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака
CN110709936A (zh) 2017-04-04 2020-01-17 肺癌蛋白质组学有限责任公司 用于早期肺癌预后的基于血浆的蛋白质概况分析
CN111562362B (zh) * 2020-04-02 2022-05-20 臻悦生物科技江苏有限公司 一组用于预测三阴乳腺癌免疫联合抗血管生成治疗效果的标志物及其应用和试剂盒
CN111440244B (zh) * 2020-04-09 2021-03-16 诺未科技（北京）有限公司 靶向vegfr2的转移性癌疫苗
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262520A (en) 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
EP0574395B1 (en) * 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
WO1997045447A1 (en) 1996-05-31 1997-12-04 The Scripps Research Institute METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DK0910382T3 (da) * 1996-04-26 2003-10-06 Genaera Corp Squalamin i kombination med andre anticancermidler til behandling af tumorer

Also Published As

Publication number Publication date
SI1156823T1 (sl) 2009-02-28
SK11132001A3 (sk) 2002-06-04
US20070036751A1 (en) 2007-02-15
US7115261B1 (en) 2006-10-03
EP1156823A1 (en) 2001-11-28
BR0008161A (pt) 2002-05-28
KR20010102043A (ko) 2001-11-15
DE60040651D1 (de) 2008-12-11
NO331072B1 (no) 2011-09-26
AU776790B2 (en) 2004-09-23
NO20013906L (no) 2001-10-09
MXPA01008110A (es) 2002-10-23
SK287357B6 (sk) 2010-08-09
PL350329A1 (en) 2002-12-02
AU3228000A (en) 2000-08-29
US7365054B2 (en) 2008-04-29
DK1156823T3 (da) 2009-01-19
CN1192796C (zh) 2005-03-16
CA2360106C (en) 2012-10-30
WO2000047228A1 (en) 2000-08-17
US7833976B2 (en) 2010-11-16
PL200919B1 (pl) 2009-02-27
ES2313883T3 (es) 2009-03-16
JP2002536419A (ja) 2002-10-29
EP1156823A4 (en) 2003-02-19
RU2236251C2 (ru) 2004-09-20
ATE412433T1 (de) 2008-11-15
HUP0200128A2 (en) 2002-05-29
CN1346279A (zh) 2002-04-24
NO20013906D0 (no) 2001-08-10
HU229520B1 (en) 2014-01-28
CZ303155B6 (cs) 2012-05-09
CA2360106A1 (en) 2000-08-17
PT1156823E (pt) 2009-01-08
CZ20012791A3 (cs) 2002-05-15
EP1156823B1 (en) 2008-10-29
JP2011207892A (ja) 2011-10-20
JP4841727B2 (ja) 2011-12-21
KR100704140B1 (ko) 2007-04-09
US20090060864A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
NO20101696L (no) Fremgangsmate for behandling av tumorer og metastaser ved bruk av en kombinasjon av anti-angiogenese og immunoterapi
Lode et al. Targeted cytokines for cancer immunotherapy
AU2017249694B2 (en) Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (CAR)-T cell
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
US20200268859A1 (en) Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
DK0851927T3 (da) Forbindelser til immunterapi og diagnosticering af tuberkulose
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
DK1349870T3 (da) Sammensætninger til terapien og diagnosen af ovariecancer
DK0662827T4 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
DE69924826D1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
ATE342976T1 (de) Cytokinrezeptor-kette
Ma et al. Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
JP2023546298A (ja) 多機能性及び多価インターロイキン－ｔｇｆ－ベータ受容体融合ポリペプチド
ATE342978T1 (de) Einkettige polypeptide enthaltend n-terminale troponin i fragmente und troponin c
RU2021108158A (ru) Новые иммуноцитокины для лечения рака
DE60237588D1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application